1. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Issue 11 (4th October 2019) Authors: Ghobrial, Irene M.; Liu, Chia‐Jen; Zavidij, Oksana; Azab, Abdel K.; Baz, Rachid; Laubach, Jacob P.; Mishima, Yuji; Armand, Philippe; Munshi, Nikhil C.; Basile, Frank; Constantine, Michael; Vredenburgh, James; Boruchov, Adam; Crilley, Pamela; Henrick, Patrick M.; Hornburg, Kalvis T. V.; Leblebjian... Journal: American journal of hematology Issue: Volume 94:Issue 11(2019:Nov.) Page Start: 1244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗